GSK invests $120 million in next-generation US biopharma manufacturing facility26 Sep 2019
Part of nearly $400 million in US manufacturing investments to deliver on the company’s pipeline and bring medicines to patients faster.
GSK is investing $120 million to expand its manufacturing facility in Upper Merion, Pennsylvania that will support the delivery of the company’s pipeline, bringing new medicines for cancer and other specialty diseases to patients faster. The investment at Upper Merion creates a technologically-advanced manufacturing hub that offers the flexibility and speed necessary when making today’s complex specialty medicines.
Emma Walmsley, CEO, GSK said: “These investments will support and accelerate the transformation of our pipeline to deliver the next generation of medicines and vaccines for patients who need them. This also underscores GSK’s longstanding commitment to making innovative medicines and vaccines here in the US.”
By bringing together the R&D and manufacturing teams in one facility in Upper Merion, we now have an even more highly skilled workforce, the technological and scientific capabilities, and the infrastructure to research potential new genetic targets and seamlessly manufacture them into new medicines. With R&D and manufacturing using the same equipment, data, and analytics, we are creating efficiencies that will significantly reduce the overall time to produce a new medicine.
The newly-outfitted manufacturing space is made to be more flexible than traditional pharmaceutical manufacturing equipment. Upper Merion uses emerging technologies in bioreactors, such as single-use and disposable components, which eliminates the need for complex retrofitting and sterilizing that is typical in most manufacturing plants. This simplifies and accelerates the process of changing from manufacturing one medicine to another medicine. A new analytical lab is also part of the facility, and the processes associated with quality and commercial testing have been streamlined to ensure medicines are ready for patient use as soon as possible.
Since 2017, GSK has invested close to $400 million dollars in US manufacturing capabilities across our vaccine and specialty portfolios, including today’s announcement. GSK has two significant R&D and manufacturing sites in Pennsylvania: Upper Merion and Upper Providence, employing approximately 3,500 people. In addition, GSK has its US corporate headquarters at Philadelphia’s Navy Yard that employs more than 1,000 people.
The Upper Merion facility will initially be producing key pipeline assets. All products are currently in clinical trials and subject to clinical trial outcomes and regulatory approval.
Funding to accelerate delivery of Univercells' vaccine portfolio
11 Oct 2019
European financing to support Univercells’ R&D investments to develop four essential and undersupplied global health vaccines to be produced at affordable prices, high quality and large volumes.Read more
Industrial-scale manufacture of therapeutic exosomes
10 Oct 2019
Coordinated purification process development service accelerates progress to clinical trials, and scale-up manufacturing.Read more
Janssen opens new biomanufacturing building in Ireland
8 Oct 2019
Expansion creates 200 new full-time jobs and increases the company’s production capacity by an additional 19,100 m2.Read more
BASF and Biomillenia join forces in microbiome research to promote healthy skin
7 Oct 2019
Research aims to identify novel dermocosmetic active ingredients via unique microbiome-on-a-chip technology.Read more
Allergan expands Refresh eye treatment portfolio
7 Oct 2019
A trifecta of relief formulated with HydroCell technology offers new artificial tear options for patients suffering from eye dryness.Read more
BASF strengthens biotechnology footprint to enter natural F&F ingredients market
3 Oct 2019
Market entrance with biotech-based natural vanillin, valencene and nootkatone.Read more
Unidose device approved for Tosymra sumatriptan spray
3 Oct 2019
Provides migraine sufferers with a convenient, patient-friendly delivery approach.Read more
One-stop-platform for plant-based nutraceuticals
2 Oct 2019
In 2020, nutra brands will look to ensure they have plant-based options across all product classes with many actively looking to move entire portfolios plant-based.Read more
BASF's new bioactive ingredient the wellness elixir for healthy skin
1 Oct 2019
The active ingredient is a 100% natural extract from the chaga mushroom, obtained using an innovative eco-friendly technology: subcritical water extraction.Read more
Arctoris secures funding to advance novel robotic drug discovery platform
1 Oct 2019
Platform will enable scientists and biotechnology entrepreneurs worldwide to make discoveries faster and more efficiently,Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation